** Shares of consumer healthcare co Kenvue KVUE.N fall ~2% to $20.33 premarket
** Co forecasts 2025 adjusted profit below estimates hit by a stronger dollar and weak demand for its cough and cold products
** Co forecasts flat to 2% growth in 2025 adjusted EPS, compared with $1.14 it earned in 2024
** Analysts expect earnings to grow 5.6% this year, or to $1.21 per share, according to estimates compiled by LSEG
** Reports Q4 sales of $3.66 billion slightly missing estimates of $3.77 billion, hit by low incidences of cold, cough and flu
** Stock fell over 20% since its stock market debut in May 2023
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。